People
Jonathan Trinh specializes in FDA regulatory matters involving drug, medical device, and combination products. Jonathan advises innovative life sciences companies navigate pre- and post-market challenges throughout their products’ lifecycles, enabling them to launch and commercialize their products in the U.S. Jonathan also applies his regulatory expertise on transactional matters and white-collar criminal defense matters involving FDA-regulated products and entities. He is a frequent author and presenter on emerging issues affecting the life sciences industry.
Jonathan’s representative experience includes:
Jonathan is a champion for diversity and inclusion, mentorship, and pro bono initiatives. Jonathan actively participates in K&S's Diverse Retreat Planning Committee, K&S's Asian American and LGBTQ+ Affinity Groups, and bar associations and non-profit organizations committed to the professional development of diverse lawyers. He represents K&S at diversity conferences and on-campus events to recruit rising leaders in the legal profession. He also maintains an active pro bono practice providing robust legal representation for undocumented individuals and LGBTQ+ individuals.
Jonathan graduated from the George Washington University Law School with a concentration in health law. During law school, he served as Editor-in-Chief of the Federal Circuit Bar Journal, President of the Asian Pacific American Law Students Association, and Vice President of the Student Health Law Association. He also interned for the Hon. Rudolph Contreras at the U.S. District Court for the District of Columbia.
J.D., George Washington University Law School
B.A. International Studies and Political Science, University of California, Berkeley, with honors
District of Columbia
Intern, Judge Rudolph Contreras, U.S. District Court for the District of Columbia
American Health Law Association
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
Advised Oaktree Acquisition Corp. II in its go-public merger with Alvotech Holdings SA, a transaction with a combined company value of $2.25 billion.
December 21, 2023
FDA Ushers in New Program for Drug Products Manufactured Using Innovative Manufacturing Technologies
August 10, 2023
FTC Revamps the “Guides Concerning the Use of Endorsements and Testimonials in Advertising”
July 12, 2023
A Pathway for Medicare Coverage for Breakthrough Devices: Take Two
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
Advised Oaktree Acquisition Corp. II in its go-public merger with Alvotech Holdings SA, a transaction with a combined company value of $2.25 billion.
December 21, 2023
FDA Ushers in New Program for Drug Products Manufactured Using Innovative Manufacturing Technologies
August 10, 2023
FTC Revamps the “Guides Concerning the Use of Endorsements and Testimonials in Advertising”
July 12, 2023
A Pathway for Medicare Coverage for Breakthrough Devices: Take Two
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
J.D., George Washington University Law School
B.A. International Studies and Political Science, University of California, Berkeley, with honors
District of Columbia
Intern, Judge Rudolph Contreras, U.S. District Court for the District of Columbia
American Health Law Association